The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...

Moderna today reported promising relative vaccine efficacy (rVE) findings from a phase 3 trial of its seasonal mRNA flu ...

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review ...

It's a shot in the arm for Cambridge, Massachusetts-based Moderna as it faces an evolving regulatory environment for vaccines ...

The Trump administration recently canceled $766 million in contracts with Moderna to develop and produce an mRNA vaccine against pandemic influenza viruses, including H5N1 avian flu. This is a tragic ...

The long and winding journey of Moderna’s mRNA flu vaccine toward regulators has come one step closer with a phase 3 win over an approved competitor shot. Moderna said its own vaccine, dubbed ...

NB.1.8.1 is one of the latest variants of COVID-19, a "slightly upgraded version" of the LP.8.1 variant that is prominent ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older ...

The FDA has updated labels on the top two COVID-19 vaccines to warn of a rare heart side effect, mostly seen in young men.

Moderna disclosed that a study of 56,000 volunteers older than 50 found that its new mRNA influenza vaccine was 27% more effective than an existing influenza shot. That would mean that it is more ...